Journey Medical Corporation (DERM) — Financial statements
Income statement, balance sheet, and cash flow for Journey Medical Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 62↑10.2% | 56↓29.1% | 79↑7.5% | 74↑16.7% | 63 | |
| Cost of Revenue | 25↑20.6% | 21↓21.7% | 27↓13.4% | 31↓4.1% | 32 | |
| Gross Profit | 37↑4.0% | 35↓32.9% | 53↑22.4% | 43↑38.1% | 31 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.48↓95.1% | 10↑30.7% | 8↓31.1% | 11↓33.9% | 17 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 44↑10.4% | 40↓8.4% | 44↓26.2% | 59↑49.3% | 40 | |
| Other Expenses | 0.00↑100.0% | -1↓135.9% | 3 | 0.00↓100.0% | 10 | |
| Operating Expenses | 45↓8.3% | 49↓10.4% | 55↓22.5% | 70↑6.8% | 66 | |
| Total Costs & Expenses | 70↑0.3% | 70↓14.1% | 81↓19.7% | 101↑3.2% | 98 | |
| Operating Results | ||||||
| Operating Income | -8↑40.3% | -14↓559.8% | -2↑92.5% | -28↑21.1% | -35 | |
| Depreciation & Amortization | 4↑23.6% | 4↓8.8% | 4↓11.7% | 4↑70.5% | 3 | |
| EBITDA | -4↑54.4% | -8↓537.1% | 2↑108.3% | -23↑29.3% | -33 | |
| EBIT | -8↑31.4% | -12↓515.9% | -2↑93.0% | -28↑22.0% | -35 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↓60.0% | -2↓41.2% | -1↑29.8% | -2↑72.1% | -7 | |
| Interest Income | 0.59↓22.2% | 0.76↑135.1% | 0.32↑436.7% | 0.06↑2900.0% | 0.00 | |
| Interest Expense | 4↑37.0% | 3↑59.0% | 2↓15.9% | 2↓71.3% | 7 | |
| Non-Operating Income | 0.00↑100.0% | -2↓1170.5% | -0.14↓579.3% | 0.03↓93.5% | 0.45 | |
| Other Income / Expenses | -3↓242.5% | -0.93↑40.1% | -2↑23.9% | -2↑72.6% | -7 | |
| Income Before Tax | -11↑22.2% | -15↓302.3% | -4↑87.7% | -30↑30.2% | -42 | |
| Income Tax Expense | 0.06↓1.6% | 0.06↓72.4% | 0.22↑250.8% | 0.06↓96.1% | 2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -11↑22.1% | -15↓280.8% | -4↑87.0% | -30↑32.7% | -44 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -11↑22.1% | -15↓280.8% | -4↑87.0% | -30↑32.7% | -44 | |
| Bottom-Line Net Income | -11↑22.1% | -15↓280.8% | -4↑87.0% | -30↑32.7% | -44 | |
| EPS (Basic) | -0.47↑34.7% | -0.72↓242.9% | -0.21↑87.6% | -1.69↑33.5% | -2.54 | |
| EPS (Diluted) | -0.47↑34.7% | -0.72↓242.9% | -0.21↑87.6% | -1.69↑33.5% | -2.54 | |
| Weighted Average Shares | 24↑19.9% | 20↑12.1% | 18↑4.0% | 18↑1.2% | 17 | |
| Weighted Average Diluted Shares | 24↑19.9% | 20↑12.1% | 18↑4.0% | 18↑1.2% | 17 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.